Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ARGX

Argen X SE ADR

924.60

Jul 23 • 3:59 PM ET +72.88 (8.56%)

925.00

Aftermarket • 5:02 PM ET +0.40 (0.04%)

Healthcare Biotechnology Netherlands Large NASD

Today, 11:35 AMargenx posts Q2 diluted EPS $7.32 as VYVGART net sales jump 60% to $1.52B and operating profit more than doubles to $494M

Peers: VRTX AMGN REGN GILD ALNY BIIB ONC ABBV BMRN LLY

| Held by: IBB CGGO FBT AVDE BBH QQQJ DFAI FBCG TGRT TOUS

Scroll to Statements

Index	-
Market Cap	57.84B
Enterprise Value	53.45B
Income	1.29B
Sales	4.16B
Book/sh	118.34
Cash/sh	70.97
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	1863
IPO	May 18, 2017

P/E	47.21
Forward P/E	25.45
PEG	0.79
P/S	13.91
P/B	7.81
P/C	13.03
P/FCF	68.90
EV/EBITDA	53.54
EV/Sales	12.85
Quick Ratio	4.87
Current Ratio	5.23
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	19.58
EPS next Y	36.33
EPS next Q	6.54
EPS this Y	37.64%
EPS next Y	34.87%
EPS next 5Y	32.39%
EPS past 3/5Y	- -
Sales past 3/5Y	116.43% 151.37%
EPS Y/Y TTM	51.88%
Sales Y/Y TTM	90.23%
EPS Q/Q	-0.66%
Sales Q/Q	83.83%
Earnings	Jul 23 BMO
EPS/Sales Surpr.	2.65% -0.34%

Insider Own	0.29%
Insider Trans	0.00%
Inst Own	45.89%
Inst Trans	-5.63%
ROA	17.37%
ROE	20.17%
ROIC	17.57%
Gross Margin	88.67%
Oper. Margin	23.33%
Profit Margin	31.09%
SMA20	3.78%
SMA50	7.24%
SMA200	11.73%
Trades

Shs Outstand	62.56M
Shs Float	62.38M
Short Float	2.33%
Short Ratio	4.30
Short Interest	1.45M
52W High	953.58 -3.04%
52W Low	566.42 63.23%
Volatility	2.38% 3.15%
ATR (14)	30.39
RSI (14)	59.39
Beta	0.46
Rel Volume	1.80
Avg Volume	337.69K
Volume	607,924

Perf Week	7.77%
Perf Month	8.34%
Perf Quarter	16.56%
Perf Half Y	13.26%
Perf YTD	9.95%
Perf Year	60.68%
Perf 3Y	68.59%
Perf 5Y	192.51%
Perf 10Y	-
Recom	1.34
Target Price	1070.34
Prev Close	851.72
Price	924.60
Change	8.56%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-10-26	Upgrade	Deutsche Bank	Hold → Buy
Dec-18-25	Downgrade	Robert W. Baird	Outperform → Neutral	$858
Nov-24-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Sep-15-25	Resumed	Truist	Buy	$918
Sep-11-25	Downgrade	Deutsche Bank	Buy → Hold
Aug-25-25	Initiated	RBC Capital Mkts	Outperform	$850
Jul-08-25	Upgrade	Deutsche Bank	Hold → Buy
Jul-03-25	Resumed	Morgan Stanley	Overweight	$700
May-13-25	Upgrade	Robert W. Baird	Neutral → Outperform	$680
Mar-17-25	Upgrade	Bernstein	Mkt Perform → Outperform
Mar-12-25	Upgrade	Deutsche Bank	Sell → Hold
Jan-17-25	Downgrade	Deutsche Bank	Hold → Sell
Nov-12-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$697
Nov-05-24	Upgrade	Scotiabank	Sector Perform → Sector Outperform	$715
Nov-01-24	Upgrade	William Blair	Mkt Perform → Outperform
Nov-01-24	Downgrade	Robert W. Baird	Outperform → Neutral	$515 → $650
Oct-10-24	Resumed	Raymond James	Strong Buy	$605
Oct-04-24	Downgrade	Deutsche Bank	Buy → Hold
Aug-06-24	Upgrade	Barclays	Equal Weight → Overweight
Jul-25-24	Upgrade	Deutsche Bank	Hold → Buy

Show Previous Ratings

Today 11:30AM	argenx VYVGART Sales Rise 60% as Pipeline Readouts Approach (InvestorsHub) +8.56%
01:00AM	argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update (GlobeNewswire)
Jul-16-26 01:00AM	argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026 (GlobeNewswire)
Jul-06-26 04:06PM	Planet Labs Upgraded, Royal Caribbean Downgraded: Updated Rankings on Top Blue-Chip Stocks (InvestorPlace)
01:12PM	This Profitable Autoimmune Biotech Trades Near A High And A Buy Point (Investor's Business Daily)
08:01AM	Loading…
Jul-04-26 08:01AM	Robinhood, Dell Lead 5 Stocks Near Buy Points With AI Tailwinds (Investor's Business Daily)
Jul-01-26 01:14PM	Argenx, Stock Of The Day, Eyes Buy Point Amid Triple-Digit Growth (Investor's Business Daily)
Jun-25-26 11:33AM	Bayer Surges After Winning Its Supreme Court Roundup Challenge (Investor's Business Daily)
Jun-24-26 10:32AM	Can Argenx Retake Its Record High - And A Buy Point - On A New Vyvgart Strategy? (Investor's Business Daily)
Jun-23-26 01:00AM	argenx to Host Autoimmune Myositis R&D Webinar (GlobeNewswire) -5.57%
Jun-03-26 01:00AM	argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026 (GlobeNewswire)
May-28-26 01:00AM	argenx to Host Myositis R&D Webinar on June 23, 2026 (GlobeNewswire)
May-27-26 01:00AM	argenx to Present at Upcoming Investor Conferences (GlobeNewswire)
May-20-26 01:20PM	Can a New Arthritis Drug Make Immunovant the Next Biotech Star? (Barrons.com)
11:38AM	2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug (Barrons.com)
08:34AM	Loading…
May-18-26 08:34AM	The Biology Came First. (Business Wire)
May-11-26 06:00AM	Inhibrx delivers differentiated cancer drug data; Fractyl starts diabetes gene therapy trial (BioPharma Dive)
May-08-26 05:20PM	argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG (GlobeNewswire)
06:07AM	FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended (BioPharma Dive)
May-07-26 09:03AM	Argenx Obliterates Profit Expectations On 'Solid Print' For Its Immunology Powerhouse (Investor's Business Daily)
08:45AM	Argenx (ARGX) tops earnings expectations despite slight revenue shortfall (InvestorsHub)
01:00AM	argenx Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-06-26 04:30PM	argenx to Present at BofA Securities 2026 Health Care Conference (GlobeNewswire)
04:01PM	argenx Announces Results of Annual General Meeting and Board of Directors' Appointment of Karen Massey as Chief Executive Officer (GlobeNewswire)
09:15AM	argenx SE (XBRU:ARGX) Q1 2026: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Apr-30-26 01:00AM	argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026 (GlobeNewswire)
Apr-18-26 01:00AM	argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP (GlobeNewswire)
Mar-20-26 04:01PM	argenx announces Annual General Meeting of Shareholders on May 6, 2026 (GlobeNewswire)
Mar-11-26 08:36AM	Deutsche Bank lifts Argenx to Buy as valuation no longer demanding (Investing.com)
Mar-09-26 08:14PM	Argenx (ARGX) 2025 Net Product Sales Rise 90% to $4.2B as First Annual Profit Reached (Insider Monkey)
06:24AM	Loading…
Mar-08-26 06:24AM	Analysts Express Mixed Opinion on Argenx SE (ARGX) Stock (Insider Monkey)
Mar-06-26 01:00AM	argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline (GlobeNewswire)
Mar-05-26 11:40AM	KMDA vs. ARGX: Which Stock Is the Better Value Option? (Zacks)
Mar-03-26 06:28AM	argenx CEO Karen Massey Reaffirms Vision 2030, Teases VYVGART Catalysts at TD Cowen Conference (MarketBeat)
Mar-02-26 11:24PM	Analyst Report: argenx SE (Morningstar Research)
Feb-26-26 06:51PM	Analyst Report: argenx SE (Morningstar Research) -5.56%
04:09PM	argenx SE (ARGNF) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Advances (GuruFocus.com)
10:59AM	argenex Q4 Earnings Call Highlights (MarketBeat)
09:01AM	Argenx Touts Positive Phase 3 Eye Disease Study Results (Benzinga)
01:00AM	argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update (GlobeNewswire)
12:30AM	argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis (GlobeNewswire)
Feb-25-26 08:17PM	Nurix Therapeutics Stock Sees RS Rating Jump To 82 (Investor's Business Daily)
07:15AM	What To Expect From argenx SE (XBRU:ARGX) Q4 2025 Earnings (GuruFocus.com)
Feb-24-26 01:14PM	CRISPR Therapeutics Stock Sees RS Rating Rise To 73 (Investor's Business Daily)
01:02PM	Xenon Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
07:33AM	Artisan Mid Cap Fund Maintains Its Confidence in Argenx's (ARGX) VYVGART (Insider Monkey)
Feb-23-26 01:00AM	argenx to Present at TD Cowen 46th Annual Healthcare Conference (GlobeNewswire)
Feb-19-26 01:00AM	argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026 (GlobeNewswire)
Feb-18-26 11:17AM	Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues (Zacks)
Feb-13-26 10:27AM	Dianthus Therapeutics Conference: DNTH Eyes Q2 2026 CIDP Phase 3 Interim Readout, Expands Pipeline Plans (MarketBeat)
Feb-11-26 11:40AM	HRMY vs. ARGX: Which Stock Is the Better Value Option? (Zacks)
Feb-06-26 08:33AM	Increased Demand for Vyvgart Boosted Argenx SE (ARGX) in Q4 (Insider Monkey)
Feb-03-26 08:58PM	Analysts May Have Underestimated Argenx SE's (ARGX) 5 year Revenue Growth (Insider Monkey)
Jan-31-26 09:36AM	Argenx SE - ADR (ARGX) Sentiments Bolstered on Vyvgart FDA Priority Review Milestone (Insider Monkey)
Jan-30-26 11:15AM	Dow Jones Leader Amgen Leads These Biotech Stocks Heading Into Q4 Earnings Season (Investor's Business Daily)
02:07AM	Argenx's (ARGX) Vyvgart Sales Outperform Expectations Across MG and CIDP Treatments (Insider Monkey)
Jan-29-26 03:03PM	Wells Fargo Analyst Sees Potential in Argenx SE's (ARGX) Vyvgart, Increases PT to $1,317 (Insider Monkey)
Jan-28-26 09:13AM	argenx SE (ARGX): A Bull Case Theory (Insider Monkey)
01:59AM	Why Argenx SE (ARGX) Stock Advanced on Commercial Execution (Insider Monkey)
Jan-26-26 07:26PM	Analyst Report: argenx SE (Morningstar Research)
11:40AM	HRMY or ARGX: Which Is the Better Value Stock Right Now? (Zacks)
Jan-13-26 01:00AM	argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG (GlobeNewswire)
Jan-12-26 04:34PM	argenx Spotlights VYVGART Sales Surge, First Profitability Year and Expanding Pipeline at JPM Conference (MarketBeat)
06:26AM	Argenx shares slip as Q4 results come in broadly in line (Investing.com)
01:00AM	argenx Highlights 2026 Strategic Priorities (GlobeNewswire)
Jan-09-26 06:38PM	Analyst Report: argenx SE (Morningstar Research)
Jan-06-26 01:00AM	argenx to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-05-26 01:00AM	argenx Announces Leadership Transition Marking Next Evolution of Growth (GlobeNewswire)
Dec-30-25 11:40AM	KROS or ARGX: Which Is the Better Value Stock Right Now? (Zacks)
Dec-18-25 08:50AM	Here Are Thursdays Top Wall Street Analyst Research Calls: Digital Realty, GE Vernova, Micron Technology, Merck & Co., Rivian, United Airlines, and More (24/7 Wall St.)
Dec-16-25 03:10PM	Meta Puts Instagram Reels On Amazon's Fire TV. How Video Fits Into Zuckerberg's AI Push. (Investor's Business Daily)
08:04AM	Stock Market Today: Dow Dips Ahead Of Jobs Report; Palantir, Tesla Drop (Live Coverage) (Investor's Business Daily)
Dec-15-25 04:34PM	Argenx Flops, As Viridian Celebrates, On Surprise Setback For Vyvgart Powerhouse (Investor's Business Daily)
01:00AM	argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease (GlobeNewswire)
Dec-13-25 08:04AM	Eli Lilly Leads Five Stocks Near Buy Points In Divided Market (Investor's Business Daily)
Dec-12-25 11:40AM	KROS vs. ARGX: Which Stock Is the Better Value Option? (Zacks)
08:22AM	Here's How AMGN Benefits From FDA Nod to Uplizna in Myasthenia Gravis (Zacks)
Nov-28-25 10:07AM	Biotechs Are On A Big Run, And Two Stocks Have Buy Points (Investor's Business Daily)
Nov-18-25 04:01PM	argenx Announces Results of Extraordinary General Meeting of Shareholders (GlobeNewswire)
02:19PM	Vera Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
Nov-13-25 07:58AM	Here's Why argenx SE (ARGX) Rose in Q3 (Insider Monkey)
Nov-11-25 01:04PM	Syndax Pharmaceuticals Stock Earns RS Rating Upgrade (Investor's Business Daily)
08:13AM	Stock Market Today: Dow Wavers After Shutdown Bill Passes; Nvidia Partner Plunges (Live Coverage) (Investor's Business Daily)
Nov-10-25 11:40AM	KROS vs. ARGX: Which Stock Is the Better Value Option? (Zacks)
Nov-04-25 10:31AM	Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View (Zacks)
Nov-03-25 09:14AM	argenx SE (ARGX) Rose due to Increased Sales of its Vyvgart Medication (Insider Monkey)
Nov-02-25 07:12PM	Analyst Report: argenx SE (Morningstar Research)
Oct-30-25 04:13PM	Insmed Screams To A 25-Year High, While IBD 50's Argenx Slides (Investor's Business Daily)
02:00AM	argenx Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Oct-29-25 11:00AM	argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients (GlobeNewswire)
Oct-28-25 12:24PM	Citi Remains Bullish on Argenx SE (ARGX) (Insider Monkey)
Oct-23-25 01:00AM	argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025 (GlobeNewswire)
Oct-22-25 04:55PM	Checking In on The Trade Desk, Bristol Myers Squibb, and Other Stocks (Motley Fool)
Oct-16-25 11:40AM	INCY or ARGX: Which Is the Better Value Stock Right Now? (Zacks)
Oct-15-25 08:15AM	Should You Be Confident in Argenx SE' (ARGX) Long-Term Profit Cycle? (Insider Monkey)
01:00AM	argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session (GlobeNewswire)
Oct-03-25 04:01PM	argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025 (GlobeNewswire)
Oct-01-25 07:52PM	Oppenheimer Reaffirms Its Outperform Rating on argenx SE (ARGX) (Insider Monkey)
Sep-30-25 12:34PM	Ginkgo Bioworks Holdings Stock Scores RS Rating Upgrade (Investor's Business Daily)
11:40AM	INCY vs. ARGX: Which Stock Is the Better Value Option? (Zacks)

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.

M.Sc.Mr. Timothy Van Hauwermeiren EMBA

CEO & Executive DirectorMs. Karen Massey

Chief Financial OfficerMr. Karl Gubitz

Chief Scientific OfficerDr. Peter Ulrichts

General Counsel & Corporate SecretaryMs. Malini Moorthy

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARGX

Argen X SE ADR

Upgrade your Finviz experience